Biotech Firm HilleVax Prices US$200 Million IPO

Biopharmaceutical company HilleVax, Inc. (Nasdaq: HLVX) began trading on the Nasdaq Global Select Market on Friday. The firm’s initial public offering is looking to raise US$200.0 million and is expected to close on May 3, 2022.

The offering consists of 11.8 million common shares selling at US$17.00 per share.

J.P. Morgan, SVB Securities, Stifel, and Guggenheim Securities act as the joint bookrunners for the said offering. The underwriters were granted a 30-day over-allotment option to purchase additional 1,764,750 shares at the same IPO price.

The Boston-based biotech company is focused on developing and commercializing novel vaccines. Its lead candidate, virus-like particle-based vaccine HIL-214, is being developed as a potential prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply